New combination tablet for type II diabetes

Janumet (sitagliptin/metformin) is a new fixed-dose combination treatment for patients with inadequately controlled type II diabetes.


Janumet provides a fixed dose of two antidiabetic agents with complementary mechanisms of action: sitagliptin, a dipeptidyl peptidase 4 inhibitor and metformin, a member of the biguanide class.


Studies have proven the efficacy of sitagliptin in combination with metformin and/or a sulfonylurea. Three further studies were conducted to demonstrate the efficacy of Janumet.1

In 1091 patients who were not satisfactorily controlled on diet and exercise alone, Janumet reduced HbA1c levels after 24 weeks to a greater extent than metformin or sitagliptin alone.

In 278 patients inadequately controlled on metformin and rosiglitazone, addition of sitagliptin reduced HbA1c levels after 18 weeks to a greater extent than addition of placebo. Similarly, addition of sitagliptin produced greater HbA1c reductions after 24 weeks than addition of placebo in 641 patients inadequately controlled on a stable dose of insulin, with or without metformin.

View Janumet drug record


  1. CHMP Assessment Report for Janumet. EMEA/H/C/000861.

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in